Teva Pharmaceutical Industries Ltd. appears optimistic about settling opioid litigation as it continues to anticipate price-fixing litigation going to trial. But the company is anticipating a return to normal performance after the pandemic and sees two branded drugs launched in the last three years as well as generics as key drivers of growth.
[Sidebar#SC126163]







